Tissue Microarray for Routine Clinical Breast Biomarker Analysis. The British Columbia Cancer Agency 2008 Experience

Overview

Journal Am J Clin Pathol

Publisher Oxford University Press

Specialty Pathology

Date 2010 May 18

PMID 20472849

Citations 8

Authors

Thomas A Thomson

Chen Zhou

Kathy Ceballos

Bryan Knight

Affiliations

Soon will be listed here.

Abstract

Clinical use of tissue microarrays for immunohistochemical analysis of breast biomarkers, namely estrogen receptor, progesterone receptor, and HER2, was instituted in our laboratory in 2008. The method has proved reliable and cost-effective. We report the results of the initial year of testing with this method.

Citing Articles

Unlocking breast cancer in Brazilian public health system: Using tissue microarray for accurate immunohistochemical evaluation with limitations in subtyping.

Ruppenthal R, Pilar E, Santos J, Coelho R, Henriques C, Uchoa D Womens Health (Lond). 2025; 21:17455057241304654.

PMID: 39745077 PMC: 11694303. DOI: 10.1177/17455057241304654.

Gene Expression Detection Assay for Cancer Clinical Use.

Narrandes S, Xu W J Cancer. 2018; 9(13):2249-2265.

PMID: 30026820 PMC: 6036716. DOI: 10.7150/jca.24744.

Breast Biomarkers-Comparison on Whole Section and Tissue Microarray Section.

Chavan S, Ravindra S, Prasad M J Clin Diagn Res. 2017; 11(3):EC40-EC44.

PMID: 28511394 PMC: 5427320. DOI: 10.7860/JCDR/2017/25088.9573.

The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Borgquist S, Zhou W, Jirstrom K, Amini R, Sollie T, Sorlie T BMC Cancer. 2015; 15:468.

PMID: 26062614 PMC: 4464713. DOI: 10.1186/s12885-015-1479-3.

Tissue microarray design and construction for scientific, industrial and diagnostic use.

Pilla D, Bosisio F, Marotta R, Faggi S, Forlani P, Falavigna M J Pathol Inform. 2013; 3:42.

PMID: 23372983 PMC: 3551499. DOI: 10.4103/2153-3539.104904.